Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rEECur
2024-516078-31-00Phase 3Authorised
- Sponsor
- University of Birmingham
- Start
- Nov 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised trial of ifosfamide, carboplatin, etoposide, topotecan, cyclophosphamide and 5 more in Ewing sarcoma and Ewing-like sarcoma (7 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival time (EFS). Planned start Nov 2024; status: authorised.
02
Drugs
ifosfamidecarboplatinetoposidetopotecancyclophosphamide
03
Conditions
Ewing sarcomaEwing-like sarcoma
Beyond the preview
Go deeper on 2024-516078-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516078-31-00.